TrialJournal of cancer research and clinical oncology2019

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.

Martin Fenner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.